Sartorius Stedim Biotech’s Generation 2 ambr 15 cell culture microbioreactor system offers increased flexibility and expanded capability for clone selection, media and feed optimization, and early process development work.
Sartorius Stedim Biotech’s Generation 2 ambr 15 cell culture microbioreactor system offers increased flexibility and expanded capability for clone selection, media and feed optimization, and early process development work. The system replicates laboratory-scale bioreactor performance at the 10–15 mL microscale and controls up to 48 single-use bioreactor cultures in parallel.
Features include new functionality and a one-year license of the company’s clone selection software. Election of clones, media, and feeds can be performed under perfusion mimic conditions to bleed large volumes of culture and quickly remove spent media from the microbioreactors. A flexible workstation layout and an expanded tip bin capacity provide greater operator walk-away time, according to the company. New culture passage steps and rapid vessel drain functionality allow for the adaptation of cell lines to different media for media screening studies to be performed in the microbioreactors.
New media mixing steps automate the creation of media blends, eliminating the need to pre-mix. Rapid vessel drain functionality for automated cell passaging and media exchanges in the microbioreactors supports cell and gene therapy applications. A new culture station design provides lower stirrer speed control suitable for more sensitive cell lines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.